The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease
Abstract
Objective We evaluated microRNAs (miRNAs) as potential biomarkers for Alzheimer disease (AD) by analyzing the expression level of miRNAs in CSF of patients with AD dementia and nonaffected control subjects. Methods Using quantitative PCR, we profiled the expression level of 728 miRNAs in CSF of nonaffected control subjects and patients with clinically ascertained AD dementia, and we further compared the expression level of candidate miRNAs in 37 control subjects and 35 patients with AD dementia. Results The level of hsa-miR-27a-3p in CSF is reduced in patients with dementia due to AD in 2 different cohorts of subjects (cohort 1: p = 0.008; cohort 2: p = 0.015; 2-tailed unpaired Welch t test). Moreover, low levels of hsa-miR-27a-3p were accompanied by high CSF tau levels and low CSF β-amyloid levels. Conclusions Our pilot study highlights hsa-miR-27a-3p as a candidate biomarker for AD and provides the groundwork for further confirmation studies in larger cohorts and in other hospitals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been reported that more miRNAs can be detected in postmortem CSF, because CSF can be contaminated by miRNAs released from degenerated brain tissues19,37.”
From Intra- and Inter-individual Variability of microRNA Levels in Human Cerebrospinal Fluid: Critical Implications for Biomarker Discovery (2017) · cites this paper as [19]
In the citing paper
“We detected a relatively smaller number of miRNAs in CSF, compared to other miRNA profiling studies19,28.”
From Intra- and Inter-individual Variability of microRNA Levels in Human Cerebrospinal Fluid: Critical Implications for Biomarker Discovery (2017) · cites this paper as [19]
Citations
Cites
Andersen, C. L., Jensen, J. L., & Ørntoft, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0496 · Cited by 7,127
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationCogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., Kelnar, K., Kemppainen, J., Brown, D., Chen, C., et al. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14103 · Cited by 943
Baraniskin, A., Kuhnhenn, J., Schlegel, U. S., Chan, A., Deckert, M., Gold, R., Maghnouj, A., Zöllner, H., Reinacher‐Schick, A., Schmiegel, W., et al. (2011) · Blood · doi:10.1182/blood-2010-09-308684 · Cited by 303
Bossers, K., Wirz, K. T. S., Meerhoff, G. F., Essing, A. H. W., van Dongen, J. W., Houba, P., Kruse, C. G., Verhaagen, J., & Swaab, D. F. (2010) · Brain · doi:10.1093/brain/awq258 · Cited by 230
Self-citationBjerke, M., Zetterberg, H., Edman, Å., Blennow, K., Wallin, A., & Andreasson, U. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110566 · Cited by 180
Self-citationmiRNA Expression Profiling: From Reference Genes to Global Mean Normalization
D′haene, B., Mestdagh, P., Hellemans, J., & Vandesompele, J. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-427-8_18 · Cited by 175
Regulated microRNAs in the CSF of patients with multiple sclerosis
Haghikia, A., Haghikia, A., Hellwig, K., Baraniskin, A., Holzmann, A., Décard, B. F., Thum, T., & Gold, R. (2012) · Neurology · doi:10.1212/wnl.0b013e3182759621 · Cited by 160
Dysregulated microRNAs in neurodegenerative disorders
Lau, P., & Strooper, B. D. (2010) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2010.01.009 · Cited by 93
Self-citationStudying micro RNA Function and Dysfunction in Alzheimer’s Disease
Lukiw, W. J., Андреева, Т. В., Grigorenko, A. P., & Rogaev, E. I. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2012.00327 · Cited by 76
Cited by
Sorted by citations
Cheng, L., Doecke, J. D., Sharples, R. A., Villemagne, V. L., Fowler, C. J., Rembach, A., Martins, R. N., Rowe, C. C., Macaulay, S. L., Masters, C. L., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.127 · Cited by 409
The complexity of Alzheimer’s disease: an evolving puzzle
Ferrari, C., & Sorbi, S. (2021) · Physiological Reviews · doi:10.1152/physrev.00015.2020 · Cited by 343
Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders
van den Berg, M. M. J., Krauskopf, J., Ramaekers, J. G., Kleinjans, J. C. S., Prickaerts, J., & Briedé, J. J. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101732 · Cited by 260
MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease
Denk, J., Boelmans, K., Siegismund, C., Lassner, D., Arlt, S., & Jahn, H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126423 · Cited by 236
Biomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224
Metadata
- Authors
- Sala Frigerio, C., Lau, P., Salta, E., Tournoy, J., Bossers, K., Vandenberghe, R., Wallin, A., Bjerke, M., Zetterberg, H., Blennow, K., & De Strooper, B.
- Affiliations
- From the VIB Center for the Biology of Disease (C.S.F., P.L., E.S., B.D.S.), Leuven; Center for Human Genetics and LIND (C.S.F., P.L., E.S., B.D.S.), and Alzheimer Research Centre KU Leuven, Leuven Institute for Neuroscience and Disease (R.V.), University of Leuven; Geriatric Medicine (J.T.), and Neurology Department (R.V.), University Hospitals Leuven; Department of Clinical and Experimental Medicine and LIND (J.T.), Laboratory for Cognitive Neurology, Department of Neurosciences (R.V.), KU Leuven,...
- Netherlands Institute for Neuroscience (NL)
- ORCID
- Venue
- Neurology
- Published
- 2013-12-10
- Volume
- 81
- Issue
- 24
- Pages
- 2103-2106
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1975366875
- Cited by
- 156
- References
- 10
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 10 · 2023: 10 · 2022: 18 · 2021: 17 · 2020: 9 · 2019: 13 · 2018: 14 · 2017: 15 · 2016: 17 · 2015: 17 · 2014: 9
- FWCI
- 10.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, microRNA, cerebrospinal fluid, biomarkers, CSF tau
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Gene Expression Regulation, Humans, Male, Middle Aged, Pilot Projects, Cohort Studies, Biomarkers, MicroRNAs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
